- Home
- REFI vs XOMA Comparison
REFI vs XOMA Comparison
Compare REFI & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | XOMA |
|---|---|---|
| Founded | 2021 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 457.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | REFI | XOMA |
|---|---|---|
| Price | $12.74 | $29.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $20.00 | ★ $69.50 |
| AVG Volume (30 Days) | ★ 99.5K | 58.2K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | ★ 16.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | 0.82 |
| Revenue | ★ $54,287,847.00 | $47,106,000.00 |
| Revenue This Year | $13.78 | $77.23 |
| Revenue Next Year | $4.07 | $17.97 |
| P/E Ratio | ★ $7.52 | $36.40 |
| Revenue Growth | N/A | ★ 118.02 |
| 52 Week Low | $11.85 | $18.35 |
| 52 Week High | $16.29 | $39.92 |
Technical Indicators
Market Signals| Indicator | REFI | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 37.26 |
| Support Level | $12.44 | $29.07 |
| Resistance Level | $12.83 | $31.44 |
| Average True Range (ATR) | 0.28 | 1.53 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 82.24 | 20.52 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.